Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model

BACKGROUND: It is widely recognised that sorafenib inhibits a range of molecular targets in renal cell carcinoma (RCC). In this study, we aim to use patient-derived RCC xenografts to delineate the angiogenic and non-angiogenic molecular targets of sorafenib therapy for advanced RCC (aRCC). METHODS:...

Descrición completa

Detalles Bibliográficos
Autores principales: Yuen, J S P, Sim, M Y, Siml, H G, Chong, T W, Lau, W K O, Cheng, C W S, Huynh, H
Formato: Texto
Idioma:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en liña:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065286/
https://www.ncbi.nlm.nih.gov/pubmed/21407223
http://dx.doi.org/10.1038/bjc.2011.55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065286/
https://www.ncbi.nlm.nih.gov/pubmed/21407223
http://dx.doi.org/10.1038/bjc.2011.55

Títulos similares